All In Biotech

Drug Trial Radar · NCT03540758

Regulation of Endogenous Glucose Production by Central KATP Channels

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 1, 2018

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Albert Einstein College of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American Diabetes Association; Rutgers University; Vanderbilt University Medical Center
First posted
May 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.

Conditions

  • Diabetes Mellitus
  • Glucose Metabolism Disorders

Interventions

  • DiazoxideDrug

    Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) during the pancreatic clamp study.

  • Nicotinic acidDrug

    Non-diabetic participants will receive nicotinic acid infusion based on weight (0.01 mg/kg/min) during the pancreatic clamp study.

  • PlaceboDrug

    Non-diabetic participants will receive placebo and undergo the pancreatic clamp study. T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Endogenous glucose production (EGP) rateTime frame: 7 hour infusions, 4 days in total, separated at least 1 month apart, up to 1 year duration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Albert Einstein College of Medicine

    The Bronx, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.